Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50

Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50.

MT NewswiresMay 7 19:10

GlycoMimetics Announces Promising Phase 3 Leukemia Drug Results

TipRanksMay 7 04:13

Lyra LYRA Phase 3 Fails; GlycoMimetics GLYC Phase 3 Dissapoints

BioPharmCatalystMay 7 03:56

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 0.2%. In

MT NewswiresMay 7 03:53

Sector Update: Health Care

Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 0.2%. In c

MT NewswiresMay 7 03:36

GlycoMimetics' Uproleselan: Hold Rating Amidst Strategic Reevaluation and Uncertain Future

TipRanksMay 7 03:05